A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Public ClinicalTrials.gov record NCT02312258. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.
Study identification
- NCT ID
- NCT02312258
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 706 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 9, 2015 (Actual)
- Primary completion
- Aug 12, 2019 (Actual)
- Completion
- Aug 26, 2022 (Actual)
- Last update posted
- Sep 21, 2023
2015 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Robert A Moss MD FACP Inc | Fountain Valley | California | 92708 | — |
| UCLA Medical Hematology and Oncology | Los Angeles | California | 90095 | — |
| North County Oncology Medical Clinic Inc | Oceanside | California | 92056 | — |
| Ventura County Hematology Oncology Specialists | Oxnard | California | 93030 | — |
| Emad Ibrahim, MD, Inc | Redlands | California | 92373 | — |
| Global Cancer Research Institute (GCRI), Inc. | San Jose | California | 95124 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | — |
| John H. Stroger Jr. Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Siouxland Hematology - Oncology Associates LLP | Sioux City | Iowa | 51101 | — |
| Appalachian Regional Healthcare | Hazard | Kentucky | 41701 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Saint Agnes Hospital - Baltimore - Hunt - PPDS | Baltimore | Maryland | 21229 | — |
| University Hospital of Wales - | Bethesda | Maryland | 20817 | — |
| Tufts Medical Center - PPDS | Boston | Massachusetts | 02111 | — |
| Herbert-Herman Cancer Center | Lansing | Michigan | 48912 | — |
| Clinical Research Alliance Inc | New York | New York | 10021 | — |
| New York Presbyterian Hospital - Weill-Cornell | New York | New York | 10021 | — |
| Cancer Care of WNC PA | Asheville | North Carolina | 28801 | — |
| UPMC Cancer Pavillion | Pittsburgh | Pennsylvania | 15232 | — |
| HOPE Cancer Center of East Texas | Tyler | Texas | 75701 | — |
| Swedish Cancer Institute | Seattle | Washington | 98109 | — |
| W VA University Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 252 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02312258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02312258 live on ClinicalTrials.gov.